57470-78-7
中文名稱
鹽酸塞利洛爾
英文名稱
Celiprolol hydrochloride
CAS
57470-78-7
EINECS 編號
260-752-2
分子式
C20H34ClN3O4
MDL 編號
MFCD00941500
分子量
415.95
MOL 文件
57470-78-7.mol
更新日期
2025/01/08 09:19:18
57470-78-7 結(jié)構(gòu)式
基本信息
中文別名
3-[3-乙酰-4-(3-叔丁胺基)-2-羥基丙氧基]苯基-1,1-二乙基脲鹽酸鹽鹽酸塞利洛爾
2,2,3,3,4,4,5,5,6-九溴聯(lián)苯醚
英文別名
3-[3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-1,1-diethylurea hydrochlorideCELIPROLOL HYDROCHLORIDE
3-(3-acetil-4-(3-tert-butilamino-2-hidroxipropoxi)fenil)-1,1-dietilureahcl
3-(3-acetyl-4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)-1,1-ure
3-(3-acetyl-4-(3-tert-butylamino-2-hydroxypropoxy)phenyl)-1,1-diethylharnsto
3-(3-acetyl-4-(3-tert-butylamino-2-hydroxypropoxy)phenyl)-1,1-diethylureahyd
celiprololclorhidrato
celiprololhydrochlorid
clorhidratodeceliprolol
ffhcl
rhc-5320a
selectrol
st1396clorhidrato
st1396hydrochlorid
st1396hydrochloride
Celipolol Hydrochloride
3-[3-acetyl-4-[3-[(tert-butyl)amino]-2-hydroxypropoxy]phenyl]-1,1-diethyluronium chloride
Urea, N-3-acetyl-4-3-(1,1-dimethylethyl)amino-2-hydroxypropoxyphenyl-N,N-diethyl-, monohydrochloride
CELIPOLOLHYDROCHLORIDE(SUBJECTTOPATENTFREE)
Celectol
所屬類別
原料藥：抗心律失常藥物理化學(xué)性質(zhì)
熔點(diǎn)197-200°C (dec.)
RTECS號YR6560000
儲存條件Refrigerator
溶解度Freely soluble in water and in methanol, soluble in ethanol (96 per cent), very slightly soluble in methylene chloride.
形態(tài)neat
顏色白色至灰白色
水溶解性Soluble in ethanol, methanol and water
CAS 數(shù)據(jù)庫57470-78-7(CAS DataBase Reference)
安全數(shù)據(jù)
警示詞警告
危險性描述H303
毒性LD50 in male mice, rats (mg/kg): 56.2, 68.3 i.v.; 1834, 3826 orally (Wendtlandt, Pittner)
鹽酸塞利洛爾價格(試劑級)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2024/11/08 | S5923 | 鹽酸塞利洛爾 Celiprolol hydrochloride | 57470-78-7 | 2mg | 795.34元 |
| 2024/11/08 | S5923 | Celiprolol hydrochloride | 57470-78-7 | 10mg | 1777.23元 |
常見問題列表
生物活性
Celiprolol是β1-adrenoceptor拮抗劑，具有部分β2受體激動劑活性。靶點(diǎn)
β1-andrenoceptor
體內(nèi)研究
Celiprolol (5 or 50 mg/kg; p.o. every day for 12 weeks) has a moderate antihypertensive action at the dose of 50 mg/kg, and significantly reduces media smooth muscle hypertrophy of the mesenteric artery in SHR.
| Animal Model: | Male spontaneously hypertensive rats (SHR) and age-matched Wistar-Kyoto (WKY) rats (8 weeks old) |
| Dosage: | 5, 50 mg/kg |
| Administration: | P.o. every day (administered in drinking water) for 12 weeks |
| Result: |
Attenuated the rise in blood pressure significantly at the dose of 50 mg/kg in SHR.
Did not significantly affect absolute heart or body weights. Reduced the average medial thickness of the mesenteric artery in SHR. |